Anticoagulants Flashcards

1
Q

examples of vitamin k antagonists

A

warfarin, acenucoumerol and phenindione

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how long do vit k antagonists take to work

A

48 to 72 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What to give if immediate anticoagulant effect required

A

give with LMWH or UH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Target INR

A

n INR which is within 0.5 units of the target value is generally satisfactory; larger deviations require dosage adjustment. Target values (rather than ranges) are now recommended.

INR 2.5 for:

treatment of deep-vein thrombosis or pulmonary embolism (including those associated with antiphospholipid syndrome or for recurrence in patients no longer receiving warfarin sodium)
atrial fibrillation
cardioversion—target INR should be achieved at least 3 weeks before cardioversion and anticoagulation should continue for at least 4 weeks after the procedure (higher target values, such as an INR of 3, can be used for up to 4 weeks before the procedure to avoid cancellations due to low INR)
dilated cardiomyopathy
mitral stenosis or regurgitation in patients with either atrial fibrillation, a history of systemic embolism, a left atrial thrombus, or an enlarged left atrium
bioprosthetic heart valves in the mitral position (treat for 3 months), or in patients with a history of systemic embolism (treat for at least 3 months), or with a left atrial thrombus at surgery (treat until clot resolves), or with other risk factors (e.g. atrial fibrillation or a low ventricular ejection fraction) [note: NICE guideline NG208 (Heart valve disease presenting in adults: investigation and management, November 2021) does not recommend anticoagulation after surgical biological heart valve replacement unless there is another indication for anticoagulation.]
acute arterial embolism requiring embolectomy (consider long-term treatment)
myocardial infarction
INR 3.5 for:

recurrent deep-vein thrombosis or pulmonary embolism in patients currently receiving anticoagulation and with an INR above 2;
Mechanical prosthetic heart valves:

the recommended target INR depends on the type and location of the valve, and patient-related risk factors
consider increasing the INR target or adding an antiplatelet drug, if an embolic event occurs whilst anticoagulated at the target INR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

role of vit k

A

blood clotting and wound healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Monitoring before warfarin

A

baseline prothrombin time (INR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

acceptable INR deviation

A

within 0.5 of the target value

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what condition has a target INR of 3.5

A

recurrent DVT and PE despite anticoagulant therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

why are anticoagulants less effective I treating clots in arteries than veins

A

clots I arteries are formed mainly of platelets and not fibrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what happens if patient experiences embolism despite being at target INR

A

consider increasing INR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

duration of warfarin for DVT and PE

A

isolated calf vein DVT - 6 weeks
VTE provoked by surgery or other transient risk factors : 3 months
unprovoked proximal DVT and PE - at least 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

treating haemorrhage and elevated INR

A

Greater than 8 with minor bleeding — stop warfarin and give phytomenadione by slow intravenous injection. The dose of phytomenadione may be repeated after 24 hours if the INR is still too high.
Restart warfarin when the INR is less than 5.

Greater than 8 with no bleeding — stop warfarin and give phytomenadione by mouth using the intravenous preparation orally (off-label use). The dose of phytomenadione may be repeated after 24 hours if the INR is still too high.
Restart warfarin when the INR is less than 5.
Between 5–8 with minor bleeding — stop warfarin and give phytomenadione by slow intravenous injection.
Restart warfarin when the INR is less than 5.
Between 5–8 with no bleeding — withhold 1 or 2 doses of warfarin and reduce subsequent maintenance dose.
If there is unexpected bleeding at therapeutic levels — always investigate possibility of underlying cause, such as unsuspected renal or gastrointestinal tract pathology.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

when do you stop warfarin before surgery

Max INR for Minor surgical procedures with low risk of bleeding

A

5 days before surgery
Minor surgical procedures with low risk of bleeding can be performed in general with an international normalized ratio (INR) of less than 2.5. However, local recommendations should be considered.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

when should warfarin restarted after surgery

A

on the evening of the surgery or the next day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how does LMWH bridging work for patients who are high risk of VTE and taking warfarin.

A

interim therapy with LMWH prior to surgery but this must be stopped at least 24 hours before surgery

if high risk bleeding surgery - restart LMWH after at least 48 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the protocol emergency surgery on patients taking warfarin

A

delay for 6- 12 hours and give IV vit k

if not possible to delay - give IV vit K and dried prothrombin complex and check INR before surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

side effects of warfarin

A

bleeding -

calciphylaxis -

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

monitoring of warfarin

A

initial baseline prothrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

side effects of warfarin

A

bleeding - small increase can trigger bleeding from thing like peptic ulcer and major devotion can cause spontaneous
nose bleeds
calciphylaxis - can lead to blood clots and skin ulcers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

monitoring of warfarin

A

initial baseline prothrombin
INR - daily or every other day until stable dose and inr
then changes in patient clinical condition deteriorates ( intercurrent illness increase INR measurement requirements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

patient and carer advice

A

consult doctor is painful skin rash
anticoagulant treatment booklet and alert card should be carried
section to record doses
avoid cranberry juice
don’t make major dietary changes
alcohol in small amounts and no more than 1-2- units in a day
avoid cut or bruising activities
let HCPs know you take warfarin before procedures and before buying medication

22
Q

drugs that enhance warfarin anticoagulant effect (bleeding risk increased)

A
mainly enzyme inhibitors 
amiaodarone
macrolides
cephlasporins
cimetidine
clopidogrel 
Dipryidamole 
fluconazole,itraconazole and miconazole
NSAIDs
omeprazole
SSRIs 
tetracyclines
venlafaxine
23
Q

drugs that reduce warfarin anticoagulant effect (bleeding risk reduced, clotting risk increased)

A
mainly enzyme inducers 
carbemazepine 
griseofulvin 
phenobarbital 
phenytoin 
rifampicyn 
st jons wart 
vit k
24
Q

examples of DOAC

A

abixaban
edoxaban
rivaroxiban
dabigatran

25
Q

indications of DOACs

A

VTE prophylaxis after hip and knee replacement (except edoxaban

treatment and secondary prevention of DVT and PE

stroke prevention in non valvular AF

rivaroxaban can be used in prevention of adverse outcomes following ACS

26
Q

advantages of DOACS vs Vit k antagonists.

A

rapid onset and ofset
fixed dosing
fewer interaction
no routine monitoring

27
Q

disadvantagesof DOACS vs Vit k antagonists.

A

short half life -strict adherence

avoid / dose reduction in renal impairment

28
Q

reversal agents

A

idarucizumab - dabigtran

andexanet alfa - apixaban or rivaroxiban

29
Q

MHRA DOAC alerts

A

increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome

vigilant with signs and symptoms of bleeding

complications during treatment

use DOAc with caution
monitor renal function and use CrCl to dose appropriately
counsel patients on signs of bleeding

30
Q

how to switch from warfarin to DOAC

A

stop warfarin and switch to DOAC after to avoid over anticoagulation

31
Q

DOAC dosing

A

apixaban twice daily (2.5mg - 5mg BD)
rivaroxaban once daily ( 10,15,20 mg OD)
edoxaban 30mg OD

32
Q

apixaban reduced dose

A

80 years or over
body weight of less than 61kg
Creatine of greater than 133 micro mol/ L

33
Q

side effects of DOAC

A

anaemia
haemorrhage
nausea and skin reactions

34
Q

avoid apixaban in CrCl of

A

less than 15ml/min

35
Q

edoxaban reduced dose

A

less than 61kg

Cr 15-50ml

36
Q

edoxaban increased dose

A

when used with
ciclospirn, dronedarone, erythromycin
ketoconazole

37
Q

Differences between LMWH and unfractionionated heparin

A

LMWH : longer duration of action, less suitable in those that are high risk of bleeding as they are not terminated as rapidly as unfractionated heparin

38
Q

monitoring edoxaban

A

liver function and repeated periodically

renal function before and then clinically indicated

39
Q

rivaroxaban indications

A

prophylaxis of VTE following knee and hip replacement
prophylaxis of stroke/ systemic embolism in non valvular AF
prophylaxis of atherothrombotic events following ACS (diff dose)
treatment of DVT/PE or prophylaxis of recurrent DVT/PE

40
Q

rivaroxaban avoid in

A

less than 15ml/min

41
Q

patient advice for taking rivaroxaban

A

take with food

problems with swallowing - mix with water or apple puree and follow immediatelywith food

42
Q

side effects of DOAC

A
abnormal hepatic function 
anaemia 
diarrhoea 
haemorrhage 
nausea and vomiting
43
Q

dabigtran antidote

A

idazaruzimab

44
Q

avoid dabigtran in

A

in severe hepatic impairment and those with liver enzymes greater than 2 times the upper limit

CrCL less than 30ml/min

45
Q

unfractionated heparin vs LMWH

A

short duration of action
useful in those with high risk of bleeding as effects can be terminated quickly

LMWH
prefferend in prevention of VTE
lower risk of heparin inducted thrombocytopenia

can be used once daily for some indications so easier to use

46
Q

side effects of heparin

A

haemorrhage - withdraw

skin reactions

heparin induced thrombocytopenia
thrmobocytosis

47
Q

What is daneparoid and what is it used for

A

alternative anticoagulant used in suspected/ confirmed HIT heparin-induced thrombocytopenia

48
Q

side effects of heparin

A

haemorrhage - withdraw unfractionated/LMWH if rapid reversal needed give protamine sulphate
hyperkalemia

skin reactions

heparin induced thrombocytopenia
thrombocytosis

49
Q

monitoring for LMWH

A

Heparin induced thrombocytopenia - platelet counts
potassium levels
platelet count before given and regular monitioring

Plasma-potassium concentration should be measured in patients at risk of hyperkalaemia before starting the heparin and monitored regularly thereafter, particularly if treatment is to be continued for longer than 7 days.

50
Q

patient advice for anticoagulants

esp warfarin and DOACs

A

avoid risk activities

inform HCPs of use

51
Q

monitoring for heparins

A

potassium levels

platelet count before given and regular monitioring

52
Q

patient advice for heparins

A

avoid risk activities

inform HCPs of use of anticoagulants